David Bowtell

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

Xin Yang, Honglin Song, Goska Leslie, Christoph Engel, Eric Hahnen, Bernd Auber, Judit Horvath, Karin Kast, Dieter Niederacher, Clare Turnbull, Richard Houlston, Helen Hanson, Chey Loveday, Jill S Dolinsky, Holly LaDuca, Susan J Ramus, Usha Menon, Adam N Rosenthal, Ian Jacobs, Simon A Gayther, et al.

Journal article  |  2020  |  Journal of the National Cancer Institute

BACKGROUND: The purpose of this study was to estimate precise age-specific tubo-ovarian carcinoma (TOC) and breast cancer (BC) ris..

Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Dane Cheasley, Abhimanyu Nigam, Magnus Zethoven, Sally Hunter, Dariush Etemadmoghadam, Timothy Semple, Prue Allan, Mark S Carey, Marta L Fernandez, Amy Dawson, Martin Kobel, David G Huntsman, Cecile Le Page, Anne-Marie Mes-Masson, Diane Provencher, Neville Hacker, Yunkai Gao, David Bowtell, Anna deFazio, Kylie L Gorringe, et al.

Journal article  |  2020  |  The Journal of Pathology

Low-grade serous ovarian carcinoma (LGSOC) is associated with a poor response to existing chemotherapy, highlighting the need to p..

Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

Emma Morrish, Anthony Copeland, Donia M Moujalled, Jason A Powell, Natasha Silke, Ann Lin, Kate E Jarman, Jarrod J Sandow, Gregor Ebert, Liana Mackiewicz, Jessica A Beach, Elizabeth L Christie, Alexander C Lewis, Giovanna Pomilio, Karla C Fischer, Laura MacPherson, David DL Bowtell, Andrew Webb, Marc Pellegrini, Mark A Dawson, et al.

Journal article  |  2020  |  Blood Advances

The specific targeting of inhibitor of apoptosis (IAP) proteins by Smac-mimetic (SM) drugs, such as birinapant, has been tested in..

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Aline Talhouk, Joshy George, Chen Wang, Timothy Budden, Tuan Zea Tan, Derek S Chiu, Stefan Kommoss, Huei San Leong, Stephanie Chen, Maria P Intermaggio, Blake Gilks, Tayyebeh M Nazeran, Mila Volchek, Wafaa Elatre, Rex C Bentley, Janine Senz, Amy Lum, Veronica Chow, Hanwei Sudderuddin, Robertson Mackenzie, et al.

Journal article  |  2020  |  Clinical Cancer Research

PURPOSE: Gene-expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple s..

Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

Katharine K Brieger, Siri Peterson, Alice W Lee, Bhramar Mukherjee, Kelly M Bakulski, Aliya Alimujiang, Hoda Anton-Culver, Michael S Anglesio, Elisa Bandera, Andrew Berchuck, David DL Bowtell, Georgia Chenevix-Trench, Kathleen R Cho, Daniel W Cramer, Anna DeFazio, Jennifer A Doherty, Renee T Fortner, Dale W Garsed, Simon A Gayther, Aleksandra Gentry-Maharaj, et al.

Journal article  |  2020  |  Gynecologic Oncology

PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regime..

Prognostic gene expression signature for high-grade serous ovarian cancer

J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow, et al.

Journal article  |  2020  |  Annals of Oncology

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies ..

Sex differences in oncogenic mutational processes.

Constance H Li, Stephenie D Prokopec, Ren X Sun, Fouad Yousif, Nathaniel Schmitz, undefined PCAWG Tumour Subtypes and Clinical Translation, Paul C Boutros, undefined PCAWG Consortium

Journal article  |  2020  |  Nature Communications

Sex differences have been observed in multiple facets of cancer epidemiology, treatment and biology, and in most cancers outside t..

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours.

Sally M Hunter, Genevieve V Dall, Maria A Doyle, Richard Lupat, Jason Li, Prue Allan, Simone M Rowley, David Bowtell, undefined AOCS, Ian G Campbell, Kylie L Gorringe

Journal article  |  2020  |  BMC Research Notes

OBJECTIVE: Ovarian fibromas and adenofibromas are rare ovarian tumours. They are benign tumours composed of spindle-like stromal c..

Drug resistance in end-stage high-grade serous ovarian cancer.

Elizabeth L Christie, Kathryn Alsop, George Au-Yeung, Ahwan Pandey, David DL Bowtell

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

ROR1 is associated with ovarian cancer progression and chemoresistance.

Dongli Liu, Miya John, Claire E Henry, Elizabeth L Christie, David DL Bowtell, Kristina Tang, Viola Heinzelmann-Schwarz, Catherine Kennedy, Jessica Boros, Anna DeFazio, Caroline E Ford

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH